drugset
drugset / Trial / NCT01841112

Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers

NCT01841112 ↗

Phase 1 Completed 65 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Safety, tolerability and pharmacokinetics of single and multiple oral doses of BI 409306 tablets in healthy Chinese and Japanese male volunteers of a known genotype as specified in the study protocol.

Timeline

Start
2013-04-22
Primary completion
2013-07-18
Completion
2013-07-18

Drugs

EvaluationDrugModalityDoseRoute
Subject OSORESNONTRINE Small molecule 25 mg Oral
Subject OSORESNONTRINE Small molecule 50 mg Oral
Subject OSORESNONTRINE Small molecule 100 mg Oral

Indications

No indication recorded.